"Number 50..."
Sena said in a tired voice. Three months since starting optimization.
"But still not perfect," Mikhail said gently.
Akira organized the data. "Activity is sufficient. Selectivity cleared. But solubility is low."
"When I increase solubility, activity drops," Sena complained.
Lina displayed a graph. Pareto frontier. Trade-off between activity and solubility.
"Typical multi-objective optimization."
Mikhail explained. "Satisfying everything simultaneously is nearly impossible. Find compromise."
"Where should we compromise?"
"Depends on clinical target values," Akira answered. "How much activity needed? How much solubility?"
Lina displayed the Target Product Profile.
"Activity: IC50 < 10 nM Solubility: > 100 μg/mL Permeability: Papp > 5×10⁻⁶ cm/s Metabolic stability: t1/2 > 60 min"
"Do we have to clear all of these?" Sena asked desperately.
"Ideally yes. But if just one is slightly off while others are good, we might proceed," Mikhail answered realistically.
Akira analyzed the current best candidate. "Compound 47. Activity 8 nM, solubility 85 μg/mL."
"Solubility is slightly short."
"But might be covered by formulation technology," Mikhail proposed.
"Formulation?"
"Salt formation, amorphization, co-crystals. Technologies to increase solubility."
Lina calculated. "As hydrochloride salt, solubility could increase 3-fold."
"Is that enough?"
"Worth trying."
Sena thought of another approach. "What if we add more hydrophilic substituents?"
"Tried that," Akira showed past data. "Compounds 23, 32, 41. All showed major activity drops."
"Why?"
"Hydrophilic groups enter hydrophobic pocket," Akira explained. "Energetically unfavorable."
"So where to add them?"
Eiji joined in. "Parts extending outside the pocket. Here, exposed to solvent."
He pointed at part of the structure.
"Add hydroxy or amino groups here."
Lina modeled. "Minimal impact on activity."
"Solubility?"
"Computationally, doubles."
Sena had hope. "So let's do that!"
"But," Akira was cautious. "Might become easier to metabolize."
"Hydroxy groups are targets for glucuronidation," Mikhail warned.
"So that's no good?"
"Could protect with fluorine," Akira proposed. "Place fluorine next to hydroxy. Becomes harder to metabolize."
Lina immediately generated the structure. "Compound 51 candidate."
Everyone stared at the screen.
Mikhail evaluated. "Activity, solubility, metabolic stability. Balanced."
"Permeability?" Sena confirmed.
Lina calculated. "PAMPA assay predicted value, 6×10⁻⁶ cm/s. Cleared."
"So this is the answer?"
"Don't know yet," Akira was realistic. "Must synthesize and measure."
"But it's the top candidate," Mikhail encouraged.
Sena gazed at the structure. "Made 50, finally one..."
"Drug design is like that," Mikhail said kindly. "Find one success from many failures."
Akira supplemented. "But all 50 weren't wasted. Learned from each."
Lina displayed SAR summary.
"Here is essential for activity. Here is metabolic site. Here affects solubility."
"Knowledge accumulated."
Sena understood. "Number 51 stands on the previous 50."
"Exactly," Mikhail nodded. "Optimization is a learning process."
Akira proposed next steps. "Synthesize Compound 51. Simultaneously make a few more analogs."
"Insurance?"
"Yes. If 51 disappoints, have next candidates."
Lina searched synthesis routes. "Synthesizable in 4 steps."
"Then results next week."
Sena resolved. "Let's do it."
Mikhail said finally. "The end of optimization isn't visible yet. But we're progressing step by step."
Akira added. "No perfect molecule exists. But there's a molecule optimal for the purpose."
"Finding it is our job."
The four gazed at Compound 51's structure. One molecule found at the end of optimization. No certainty yet. But hope exists.
"I'll work hard on synthesis," Sena smiled.
"Looking forward to the data," Lina smiled.
The optimization journey continues. But the goal felt a bit closer.